Essity AB

https://www.essity.com/

Essity AB (STO: ESSITY-B), headquartered in Stockholm, Sweden, is a leading global hygiene and health company dedicated to improving well-being through essential, everyday products and solutions. Originally spun off from the Swedish timber and pulp group SCA in 2017, Essity has rapidly evolved into a formidable, dedicated health powerhouse operating in approximately 150 countries. The company operates under a clear, purpose-driven mission to "break barriers to well-being," actively working to dismantle social stigmas surrounding conditions like incontinence and menstruation while delivering high-quality care products to consumers, patients, and businesses worldwide.

The company's expansive product portfolio is organized into four core business areas: Health & Medical, Personal Care, Consumer Tissue, and Professional Hygiene. Essity holds the number one or two market position in roughly 90% of its branded sales globally. Its portfolio is anchored by ubiquitous, billion-dollar flagship brands like Tork (professional hygiene) and TENA (incontinence care), alongside leading regional consumer brands like Libero, Zewa, Nosotras, and Saba. In a strategic bid to aggressively capture higher-margin, value-added segments, Essity recently executed a major expansion in North America, successfully completing the acquisition of Edgewell Personal Care's feminine care business—which includes household names like Carefree, Stayfree, and o.b.—in early 2026.

Currently guided by President and CEO Ulrika Kolsrud, who took the helm in mid-2025, Essity is operating with a renewed, highly disciplined focus on capital allocation, margin expansion, and advanced sustainability. Moving through the first half of 2026, the company continues to demonstrate strong financial resilience following its strategic divestment of the Vinda business to streamline its portfolio. In its Q1 2026 results, Essity reported expanded EBITA margins, captured increased market shares, and announced a robust SEK 3 billion share buyback program. By heavily investing in digital transformation—such as integrating AI to optimize its supply chains and launching smart, sensor-driven B2B ecosystems like Tork Vision Cleaning—Essity remains an indispensable, forward-looking architect of global health and hygiene.

Latest updates

Essity Sales Slip as Acquisition Impacted by Pricing Pressure

Event summary

  • Essity's Q1 2026 net sales decreased 5.1% year-over-year to SEK 33.18 billion, despite a SEK 528 million increase when excluding currency translation effects.
  • Organic sales grew 0.4%, driven by a 1.1% volume increase offset by a 0.7% price/mix decline.
  • The acquisition of Edgewell's feminine care business, completed February 2, 2026, contributed 1.1% to net sales.
  • Essity announced a new SEK 3 billion share buyback program commencing May 11, 2026.
  • EBITA margin excl. IAC increased to 13.9%, a 0.4 percentage point improvement year-over-year.

The big picture

Essity's Q1 2026 results highlight a complex interplay of factors impacting the hygiene and health products sector. While volume growth and margin expansion are positive signs, the decline in net sales and pricing pressure suggest a challenging operating environment. The Edgewell acquisition, while strategically aligned, introduces integration risks and requires careful execution to deliver anticipated returns. The company's ability to navigate geopolitical turbulence and adapt to changing consumer behavior will be key to its long-term success.

What we're watching

Pricing Dynamics
The negative price/mix effect suggests weakening pricing power, which could be a symptom of broader inflationary pressures or increased competition. How Essity manages this dynamic will be crucial for sustaining margin growth.
Integration Risk
While the Edgewell acquisition boosted sales, the long-term success hinges on effective integration and realization of synergies. Whether Essity can successfully leverage the Carefree, Stayfree, Playtex, and o.b. brands remains to be seen.
Consumer Shifts
The decline in Consumer Tissue sales, partially attributed to Private Label, signals a potential shift in consumer preferences. The pace at which Essity adapts its product offerings to meet evolving consumer demands will impact future performance.

Essity Authorizes SEK 3 Billion Share Buyback

Event summary

  • Essity's Board approved a SEK 3 billion share buyback program for Class B shares.
  • The program will run from May 11, 2026, until the 2027 Annual General Meeting.
  • The repurchase will be funded by current operating cash flow after dividends.
  • The buyback program is capped at 10% of total shares outstanding and repurchased shares are expected to be cancelled.
  • Essity currently holds 1,240,123 Class B shares in treasury.

The big picture

Essity’s decision to initiate a substantial share buyback program, funded by operating cash flow, suggests a belief that the company’s stock is undervalued and that alternative investment opportunities offer limited returns. This move aligns with a broader trend among European consumer staples companies to prioritize shareholder returns amidst a challenging macroeconomic environment and limited organic growth prospects. The program's size, representing a significant portion of Essity's market capitalization, indicates a strong commitment to this strategy.

What we're watching

Capital Discipline
The commitment to share buybacks as a recurring capital allocation strategy signals confidence in Essity’s future cash flow generation and a willingness to return capital to shareholders, potentially limiting investment in growth initiatives.
Shareholder Sentiment
The program’s execution and pace will be closely watched by investors to gauge management’s view on Essity’s valuation and its commitment to enhancing shareholder value.
Financial Flexibility
The reliance on operating cash flow to fund the buyback program will highlight Essity’s ability to balance shareholder returns with ongoing investment needs and potential future acquisitions.

Essity Reduces Share Capital, Authorizes Buybacks Amidst Board Stability

Event summary

  • Essity held its 2026 Annual General Meeting in Stockholm on March 26, 2026.
  • A dividend of SEK 8.75 per share was approved for the 2025 financial year, with a record date of March 30, 2026.
  • The company reduced share capital by cancelling 11,109,318 Class B shares (approximately 1.6% of total shares) and implemented a bonus issue.
  • The Board of Directors was authorized to decide on share buybacks and transfers of repurchased shares.
  • Jan Gurander was re-elected Chairman of the Board, and Ernst & Young AB was appointed auditor until the end of 2027.

The big picture

Essity's AGM reveals a focus on shareholder returns and capital structure optimization. The share capital reduction and buyback authorization are unusual moves, suggesting management believes the stock is undervalued or that returning capital to shareholders is a higher priority than reinvesting in growth. This comes amidst a broader trend of consumer staples companies reassessing their capital deployment strategies in a higher interest rate environment.

What we're watching

Capital Returns
The authorization for share buybacks signals a potential shift in Essity’s capital allocation strategy, and the scale of any future buyback programs will indicate management’s confidence in future earnings and valuation.
Shareholder Composition
The share capital reduction and bonus issue, coupled with the buyback authorization, could significantly alter Essity’s shareholder base, potentially impacting voting power and investor sentiment.
Governance Stability
The consistent re-election of board members and Jan Gurander as Chairman suggests a stable governance structure, but the composition of the Remuneration and Audit Committees warrants ongoing scrutiny for potential conflicts of interest.

Essity to Report Q1 2026 Results Amidst Shifting Hygiene Market

Event summary

  • Essity will release its Q1 2026 interim report on April 23, 2026, at 07:00 CET.
  • A live webcast and teleconference will follow at 09:00 CET, featuring CEO Ulrika Kolsrud and CFO Fredrik Rystedt.
  • Conference call details are provided for UK, USA, and Sweden.
  • Sandra Åberg (VP, Investor Relations) and Per Lorentz (VP, Corporate Affairs) are listed as contact points.

The big picture

Essity, a major player in the global hygiene and health market, faces ongoing pressure from raw material costs and changing consumer behavior. The Q1 2026 report will provide insight into how the company is navigating these challenges and whether its strategic initiatives are gaining traction. Investor scrutiny will focus on margin performance and the effectiveness of innovation efforts in a competitive landscape.

What we're watching

Market Trends
The report will likely reveal the impact of evolving consumer preferences and potential inflationary pressures on Essity's core product categories, particularly given recent shifts in disposable income.
Cost Management
Given the current macroeconomic environment, the ability of Essity to maintain margins will be a key indicator of operational efficiency and pricing power.
Innovation Pipeline
The pace at which Essity can introduce and scale new, higher-margin products will be crucial for offsetting commodity cost increases and maintaining growth momentum.

Essity Appoints New CDIO Amidst Digital Transformation Push

Event summary

  • Essity has appointed Niklas Westin Sundberg as Chief Digital & Information Officer, effective April 15, 2026.
  • Carl-Magnus Månsson is departing Essity to pursue a new external role.
  • Sundberg brings over 20 years of experience in digital development from companies like Kuehne+Nagel and ASSA ABLOY.
  • Sundberg will report directly to Essity’s President and CEO, Ulrika Kolsrud, and join the Executive Management Team.

The big picture

Essity’s appointment of a new CDIO underscores the increasing importance of digital transformation within the consumer goods sector. The company, with approximately €16 billion in annual revenue, is clearly prioritizing digital initiatives to enhance customer experience and operational efficiency. This move suggests a potential acceleration of Essity’s digital roadmap, likely involving increased investment in areas like AI and data analytics.

What we're watching

Execution Risk
Sundberg’s success will hinge on his ability to rapidly integrate and execute Essity’s digital strategy, given his relatively short timeframe before assuming the role.
Strategic Alignment
How Sundberg’s experience in logistics (Kuehne+Nagel) and security (ASSA ABLOY) will be applied to Essity’s consumer-facing hygiene and health product lines warrants observation.
Governance Dynamics
The departure of Carl-Magnus Månsson, coupled with Sundberg’s arrival, may signal a shift in Essity’s digital governance and decision-making processes, which could impact future investments.

Essity to Outline Growth Strategy at Capital Markets Day

Event summary

  • Essity will host a Capital Markets Day on May 7, 2026, in Gothenburg, Sweden.
  • CEO Ulrika Kolsrud and the Executive Management Team will present the company’s strategy for profitable growth and financial targets.
  • The event includes tours of Essity’s R&D operations in Gothenburg and production facilities in Lilla Edet (tissue mill) and Falkenberg (incontinence/diaper products).
  • Lilla Edet is the world’s first large-scale tissue mill operating without fossil CO₂ emissions.
  • Registration is required by April 1, 2026, with priority given to institutional investors, analysts, and media.

The big picture

Essity's Capital Markets Day signals a continued focus on both sustainable operations and agile supply chains, reflecting broader industry pressures and consumer demand. The company, with approximately €12.4 billion in revenue in 2024, is positioning itself to navigate evolving consumer preferences and regulatory landscapes within the competitive personal care and hygiene sector. The prioritization of institutional investors for the event underscores the importance of maintaining strong investor confidence.

What we're watching

Sustainability
The reliance on biogas and renewable electricity at Lilla Edet suggests a broader commitment to decarbonization; investors should assess the scalability and cost-effectiveness of this approach across other facilities.
Supply Chain
Falkenberg’s focus on agile processes highlights the need for resilience in a volatile market; the company’s ability to maintain efficient supply chains will be crucial for meeting demand.
Innovation
The emphasis on R&D and product demonstrations indicates a strategic focus on innovation; the success of these initiatives will determine Essity’s ability to maintain a competitive edge in the personal care market.

Essity Bolsters North American Footprint with Edgewell Feminine Care Acquisition

Event summary

  • Essity has completed the acquisition of Edgewell Personal Care’s feminine care business for USD 340 million.
  • The acquisition includes brands like Carefree, Stayfree, o.b. in North America and global rights for Playtex.
  • The deal incorporates a Dover, Delaware production facility and will consolidate operations into Essity's accounts effective February 2, 2026.
  • The purchase price was structured on a cash and debt-free basis, amounting to approximately SEK 3 billion.

The big picture

This acquisition represents Essity’s continued push into the US market, the world’s largest hygiene market, and a strategic shift towards higher-margin categories. The $340 million price tag is relatively modest compared to Essity’s overall scale, suggesting a targeted acquisition aimed at bolstering its North American presence rather than a transformative deal. The move also highlights the ongoing consolidation within the personal care sector as companies seek to optimize portfolios and gain scale.

What we're watching

Integration Risk
The success of this acquisition hinges on Essity’s ability to effectively integrate Edgewell’s brands and operations, particularly the Dover facility, without disrupting existing supply chains or incurring unexpected costs.
Market Share
Essity's ability to leverage its existing distribution network and marketing expertise will determine whether it can significantly increase market share for the acquired brands in the competitive North American feminine care market.
Brand Resonance
Consumer preferences in feminine care are evolving rapidly; Essity must adapt the acquired brands to meet changing demands and maintain relevance among younger demographics.

Essity Secures €400M EIB Loan to Fuel Innovation

Event summary

  • Essity secured a €400 million loan from the European Investment Bank (EIB).
  • The loan carries a 7-year tenor and will fund research, development, and innovation initiatives across Essity's business areas.
  • The EIB, the long-term lending institution of the European Union, aims to bolster EU competitiveness and sustainable development.
  • Ulrika Kolsrud, Essity's CEO, stated the agreement will strengthen the company's innovation capabilities.

The big picture

This €400 million loan underscores the EIB’s focus on supporting European companies driving innovation in strategic sectors like hygiene and health. The deal provides Essity with a significant capital injection at a time when consumer preferences are shifting towards sustainable and technologically advanced products, and regulatory pressure to reduce environmental impact is intensifying. Securing this financing demonstrates Essity’s credibility and commitment to long-term growth within the EU market.

What we're watching

Financial Leverage
The favorable terms of the EIB loan suggest Essity is viewed as a low-risk borrower, but increased debt levels will need to be managed alongside ongoing operational performance.
Innovation ROI
The success of this investment hinges on Essity’s ability to translate R&D spending into commercially viable products and services that generate a return on investment.
EU Policy Alignment
Essity’s commitment to sustainability and the circular economy, as highlighted by the EIB, indicates a strategic alignment with EU policy goals that could influence future funding opportunities and regulatory scrutiny.

Essity Earns Top CDP Ratings, Signaling Growing Investor Focus on Fiber Sourcing

Event summary

  • Essity achieved a spot on CDP’s ‘A List’ for forest stewardship and an ‘A-’ rating for climate performance in 2025.
  • The CDP assessment involved over 22,000 companies, representing roughly two-thirds of global market capitalization.
  • Essity aims to reduce emissions by 35% across its value chain by 2030, targeting net-zero emissions by 2050.
  • As a major buyer of wood-based fiber, Essity commits to sourcing certified materials via FSC and PEFC chain-of-custody systems.

The big picture

Essity’s recognition by CDP underscores the growing importance of environmental, social, and governance (ESG) factors in investment decisions. The hygiene and health sector faces increasing pressure to demonstrate sustainable sourcing and reduce its environmental footprint, particularly concerning raw materials like wood fiber. This CDP ranking provides a benchmark against which Essity’s progress toward its 2050 net-zero target will be measured, and highlights the rising influence of third-party assessments on corporate reputation and investor confidence.

What we're watching

Supply Chain Risk
Increased scrutiny of wood fiber sourcing practices will likely intensify, potentially impacting Essity’s procurement costs and supplier relationships as demand for certified materials rises.
Net Zero Transition
The feasibility of Essity’s 2030 emissions reduction target, particularly across its extensive value chain, will be a key indicator of its commitment to net-zero goals and its ability to manage scope 3 emissions.
Investor Sentiment
Continued strong CDP ratings will likely bolster Essity’s ESG profile and attract investors prioritizing sustainability, but any future downgrades could trigger negative sentiment and impact valuation.

Essity Posts Margin Gains Amidst Sales Decline, Pursues North American Expansion

Event summary

  • Essity's Q4 2025 net sales decreased 8.2% year-over-year to SEK 34.695 billion, with organic sales down 1.1%.
  • Full-year 2025 net sales decreased 4.8% to SEK 138.494 billion, but organic sales grew 0.9%.
  • EBITA margin excl. IAC increased to 14.7% in Q4 2025 and 14.1% for the full year, demonstrating margin resilience.
  • Essity acquired Edgewell's feminine care business in North America, including Carefree, Stayfree, and Playtex brands, expected to close in Q1 2026.
  • The Board proposes a 6% increase in the dividend to SEK 8.75 per share.

The big picture

Essity's results highlight a complex dynamic: a resilient margin profile offsetting a decline in sales. The acquisition of Edgewell's feminine care business signals a strategic bet on North American expansion and a desire to diversify beyond its core European markets. However, the company's stated ambition to accelerate growth suggests an acknowledgement that organic performance needs improvement, and the new organizational structure represents a significant shift in operating strategy.

What we're watching

Integration Risk
The success of the Edgewell acquisition hinges on Essity's ability to integrate the new brands and operations effectively, avoiding disruption and realizing anticipated synergies.
Pricing Power
Whether Essity can sustain its margin improvements will depend on its ability to manage pricing pressures and maintain a favorable product mix in a challenging market environment.
Growth Trajectory
The effectiveness of Essity’s new decentralized organization and cost-saving initiatives will determine if the company can accelerate its growth rate and achieve its stated financial targets.

Essity to Outline Growth Strategy at May 2026 Capital Markets Day

Event summary

  • Essity will host a Capital Markets Day on May 7, 2026, in Gothenburg, Sweden.
  • CEO Ulrika Kolsrud and the Executive Management Team will present the company’s strategy for profitable volume growth.
  • The event will include virtual attendance options and afternoon tours of R&D and production facilities.
  • The Capital Markets Day is intended for institutional investors, analysts, and media.

The big picture

Essity, a significant player in the €300+ billion global hygiene and health market, is facing increased competition and inflationary pressures. This Capital Markets Day provides a crucial opportunity to understand how the company intends to navigate these challenges and deliver on its growth promises. The event’s focus on R&D and production facilities suggests a potential emphasis on operational efficiency and innovation as key drivers of future performance.

What we're watching

Growth Execution
The success of Essity’s stated goal of profitable volume growth will hinge on the specifics of the initiatives presented, and whether they address ongoing inflationary pressures impacting consumer spending.
R&D Investment
The planned facility tours suggest a focus on innovation; the extent of R&D investment and its alignment with evolving consumer preferences in hygiene and health will be a key indicator of long-term competitiveness.
Financial Targets
The company’s ability to accelerate the achievement of its financial targets will be scrutinized, particularly given the current macroeconomic environment and potential for volatility in raw material costs.

Essity Lawsuit Discontinued, Vinda Sale Link Emerges

Event summary

  • Funds initiated legal proceedings against Essity in December 2024 concerning bond loans maturing in 2029, 2030, and 2031.
  • Essity received a request for early redemption from investors on October 17, 2024, triggering the lawsuit.
  • The lawsuit was discontinued before reaching a court decision, with an agreement including a stipulation regarding claims related to Essity’s sale of its Vinda shares.
  • Essity maintains the lawsuit was unfounded and has not provided any compensation to the funds.

The big picture

The discontinued lawsuit reveals a disagreement between Essity and investors regarding the terms of bond loans, potentially stemming from concerns about the company's financial health or the impact of strategic decisions like the Vinda sale. While Essity denies any wrongdoing, the incident underscores the importance of maintaining strong investor relations and proactively addressing concerns about debt obligations, especially in a rising interest rate environment. The agreement’s conditions regarding Vinda suggest a more complex situation than initially presented.

What we're watching

Governance Dynamics
The agreement’s stipulation regarding claims related to the Vinda sale suggests a potential ongoing sensitivity around the divestiture and its financial implications, which could influence future strategic decisions.
Investor Sentiment
How the market interprets Essity’s stance that the lawsuit was unfounded will influence investor confidence in the company's financial risk management and transparency.
Debt Management
The early redemption request and subsequent lawsuit highlight potential vulnerabilities in Essity’s debt structure, and the company’s ability to manage investor relations around its bond offerings warrants close monitoring.

Essity Restructures to Accelerate Growth, Reveals Proforma Financials

Event summary

  • Essity will reorganize its business areas effective January 1, 2026, into Health & Medical, Personal Care, Consumer Tissue, and Professional Hygiene.
  • The restructuring aims to accelerate growth and achieve financial targets more rapidly.
  • Essity has released proforma financial reporting for 2023, 2024, and 9M 2025 to reflect the new structure.
  • The company's net sales for 9M 2025 totaled SEK 103.8 billion, with Professional Hygiene contributing SEK 26.9 billion.

The big picture

Essity's reorganization signals a strategic shift towards greater operational focus and potentially improved agility in a competitive consumer goods market. The proforma reporting provides a baseline for evaluating the success of this restructuring, but the company's ability to deliver on accelerated growth targets will depend on effective integration and execution. The move also suggests a desire to better isolate and manage the performance of its diverse portfolio of brands, ranging from premium healthcare products to mass-market tissue.

What we're watching

Margin Pressure
Whether Essity can maintain or improve gross margins within the newly formed Personal Care segment, given the competitive landscape and potential for promotional activity.
Integration Risk
The pace at which synergies and operational efficiencies are realized across the business areas, particularly in Professional Hygiene, which appears to have a lower margin profile.
Regional Dynamics
How Essity’s geographic exposure, particularly in Europe and Latin America, will impact performance given differing economic conditions and consumer preferences.
CID: 132